Therefore, new effective therapeutic options including cisplatin (CDDP), which is currently applied for TNBC (triple negative: ER-/PR-/HER2- BC) tumors, are considered for the treatment regimens of patients with luminal BC [6]. This evidence concerns the gene PGR and breast cancer.